Atypical Endometrial Hyperplasia
25
9
14
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
4.0%
1 terminated out of 25 trials
85.7%
-0.8% vs benchmark
4%
1 trials in Phase 3/4
50%
3 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (25)
SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer (Phase 1)
Endometrial Cancer Vaginal Fluid Specimen Collection Study
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Intrauterine Injection of Type III Collage in FST of EC/AEH
Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia
Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy
Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia
Ultrasound and Histology in AEH and Early EEC Treated Conservatively
Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer
Metformin Plus Megestrol Acetate As a Fertility-sparing Treatment in Patients with Atypical Endometrial Hyperplasia
Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia
Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia
Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells
Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia